NASDAQ:MEDPMedpace Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Medpace Holdings Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $68.08 -3.84 (-5.34 %) (As of 04/6/2020 06:43 AM ET) Add Compare Share Today's Range$66.78Now: $68.08▼$72.7550-Day Range$61.71MA: $85.42▼$101.9552-Week Range$52.84Now: $68.08▼$109.09Volume357,399 shsAverage Volume537,512 shsMarket Capitalization$2.48 billionP/E Ratio25.69Dividend YieldN/ABeta1.33 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Medpace Holdings, Inc., a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas. Its drug development services include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is headquartered in Cincinnati, Ohio.Read More Beat the Market (BTM) Rank™ 2.1 Analyst's Opinion Consensus RatingMedpace has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 2 buy ratings, 2 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $76.20, Medpace has a potential upside of 11.9% from its current price of $68.08.Amount of Analyst CoverageMedpace has only been the subject of 4 research reports in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesMedpace has received 286 “outperform” votes. (Add your “outperform” vote.)Underperform VotesMedpace has received 299 “underperform” votes. (Add your “underperform” vote.)Community SentimentMedpace has received 51.11% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Medpace and other stocks. Vote “Outperform” if you believe MEDP will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MEDP will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldMedpace does not currently pay a dividend.Dividend GrowthMedpace does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Medpace insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 24.20% of the stock of Medpace is held by insiders.Percentage Held by Institutions79.63% of the stock of Medpace is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Medpace are expected to grow by 26.37% in the coming year, from $2.92 to $3.69 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Medpace is 25.69, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 11.29.Price to Earnings Ratio vs. SectorThe P/E ratio of Medpace is 25.69, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 19.02.Price to Book Value per Share RatioMedpace has a P/B Ratio of 3.38. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 2.1Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.35 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Commercial physical research Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MEDP Previous Symbol CUSIPN/A CIK1668397 Webhttp://www.medpace.com/ Phone513-579-9911Debt Debt-to-Equity Ratio0.06 Current Ratio0.92 Quick Ratio0.92Price-To-Earnings Trailing P/E Ratio25.69 Forward P/E Ratio23.32 P/E GrowthN/A Sales & Book Value Annual Sales$860.97 million Price / Sales2.88 Cash Flow$3.79 per share Price / Cash Flow17.95 Book Value$20.16 per share Price / Book3.38Profitability EPS (Most Recent Fiscal Year)$3.02 Net Income$100.44 million Net Margins11.67% Return on Equity16.80% Return on Assets10.69%Miscellaneous Employees3,500 Outstanding Shares36,390,000Market Cap$2.48 billion Next Earnings Date5/4/2020 (Estimated) OptionableOptionable Receive MEDP News and Ratings via Email Sign-up to receive the latest news and ratings for MEDP and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:MEDP Rates by TradingView Medpace (NASDAQ:MEDP) Frequently Asked Questions How has Medpace's stock been impacted by COVID-19 (Coronavirus)? Medpace's stock was trading at $83.64 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, MEDP stock has decreased by 18.6% and is now trading at $68.08. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Medpace? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last year. There are currently 1 sell rating, 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Medpace. When is Medpace's next earnings date? Medpace is scheduled to release its next quarterly earnings announcement on Monday, May 4th 2020. View our earnings forecast for Medpace. How were Medpace's earnings last quarter? Medpace Holdings Inc (NASDAQ:MEDP) released its quarterly earnings data on Monday, February, 24th. The company reported $0.85 earnings per share for the quarter, beating the consensus estimate of $0.75 by $0.10. The business had revenue of $229.89 million for the quarter, compared to analysts' expectations of $221.73 million. Medpace had a net margin of 11.67% and a return on equity of 16.80%. Medpace's revenue was up 19.7% on a year-over-year basis. During the same period last year, the business earned $0.76 EPS. View Medpace's earnings history. What guidance has Medpace issued on next quarter's earnings? Medpace issued an update on its FY 2020 After-Hours earnings guidance on Monday, February, 24th. The company provided earnings per share guidance of 3.24-3.34 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.28. The company issued revenue guidance of $975M - 1.005 billion, compared to the consensus revenue estimate of $977.76 million. What price target have analysts set for MEDP? 5 analysts have issued 12 month price targets for Medpace's shares. Their forecasts range from $46.00 to $99.00. On average, they expect Medpace's stock price to reach $76.20 in the next twelve months. This suggests a possible upside of 11.9% from the stock's current price. View analysts' price targets for Medpace. Has Medpace been receiving favorable news coverage? Media headlines about MEDP stock have trended very negative on Monday, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Medpace earned a coverage optimism score of -3.3 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutMedpace. Who are some of Medpace's key competitors? Some companies that are related to Medpace include EXACT Sciences (EXAS), Icon (ICLR), Charles River Laboratories Intl. (CRL), PPD (PPD), Exelixis (EXEL), PRA Health Sciences (PRAH), BTG (BTGGF), Syneos Health (SYNH), National Research (NRC), Precigen (PGEN), Intrexon (XON), STARPHARMA HOLD/S (SPHRY), Luna Innovations (LUNA), Anavex Life Sciences (AVXL) and Auxly Cannabis Group (CBWTF). What other stocks do shareholders of Medpace own? Based on aggregate information from My MarketBeat watchlists, some companies that other Medpace investors own include NVIDIA (NVDA), EXACT Sciences (EXAS), Alibaba Group (BABA), Adobe (ADBE), Baidu (BIDU), Paycom Software (PAYC), Cyberark Software (CYBR), Paypal (PYPL), Veeva Systems (VEEV) and Fortinet (FTNT). Who are Medpace's key executives? Medpace's management team includes the following people: Dr. August James Troendle, Chairman, Pres & CEO (Age 63)Mr. Jesse J. Geiger, CFO & Chief Operating Officer of Laboratory Operations (Age 45)Ms. Susan E. Burwig, Exec. VP of Operations (Age 56)Mr. Stephen P. Ewald, Gen. Counsel & Corp. Sec. (Age 50)Mr. Todd Meyers, VP of Bus. Devel. & Marketing When did Medpace IPO? (MEDP) raised $150 million in an initial public offering on Thursday, August 11th 2016. The company issued 7,000,000 shares at a price of $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers. What is Medpace's stock symbol? Medpace trades on the NASDAQ under the ticker symbol "MEDP." Who are Medpace's major shareholders? Medpace's stock is owned by a variety of institutional and retail investors. Top institutional investors include McGuire Investment Group LLC (0.14%). Company insiders that own Medpace stock include August J Troendle, Jesse J Geiger, Medpace Investors, Llc, Medpace Limited Partnership and Stephen P Ewald. View institutional ownership trends for Medpace. Which institutional investors are buying Medpace stock? MEDP stock was bought by a variety of institutional investors in the last quarter, including McGuire Investment Group LLC. View insider buying and selling activity for Medpace. How do I buy shares of Medpace? Shares of MEDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Medpace's stock price today? One share of MEDP stock can currently be purchased for approximately $68.08. How big of a company is Medpace? Medpace has a market capitalization of $2.48 billion and generates $860.97 million in revenue each year. The company earns $100.44 million in net income (profit) each year or $3.02 on an earnings per share basis. Medpace employs 3,500 workers across the globe. View additional information about Medpace. What is Medpace's official website? The official website for Medpace is http://www.medpace.com/. How can I contact Medpace? Medpace's mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The company can be reached via phone at 513-579-9911 or via email at [email protected] This page was last updated on 4/6/2020 by MarketBeat.com StaffFeatured Article: What are the disadvantages of after-hours trading?
